Cargando…

Antineoplastic activity of biogenic silver and gold nanoparticles to combat leukemia: Beginning a new era in cancer theragnostic

The American Cancer Society estimated around 61,090 new cases of leukemia were diagnosed, and around 23,660 people died from this disease in the United States alone in 2021. Due to its burden on society, there is an unmet need to explore innovative approaches to overcome leukemia. Among different st...

Descripción completa

Detalles Bibliográficos
Autores principales: Mostafavi, Ebrahim, Zarepour, Atefeh, Barabadi, Hamed, Zarrabi, Ali, Truong, Linh B., Medina-Cruz, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171450/
https://www.ncbi.nlm.nih.gov/pubmed/35686001
http://dx.doi.org/10.1016/j.btre.2022.e00714
_version_ 1784721668951769088
author Mostafavi, Ebrahim
Zarepour, Atefeh
Barabadi, Hamed
Zarrabi, Ali
Truong, Linh B.
Medina-Cruz, David
author_facet Mostafavi, Ebrahim
Zarepour, Atefeh
Barabadi, Hamed
Zarrabi, Ali
Truong, Linh B.
Medina-Cruz, David
author_sort Mostafavi, Ebrahim
collection PubMed
description The American Cancer Society estimated around 61,090 new cases of leukemia were diagnosed, and around 23,660 people died from this disease in the United States alone in 2021. Due to its burden on society, there is an unmet need to explore innovative approaches to overcome leukemia. Among different strategies that have been explored, nanotechnology appears to be a promising and effective approach for therapeutics. Specifically, biogenic silver and gold nanoparticles (NPs) have attracted significant attention for their antineoplastic activity toward leukemia cancer cells due to their unique physicochemical properties. Indeed, these nanostructures have emerged as useful approaches in anti-leukemic applications, either as carriers to enhance drug bioavailability and its targeted delivery to a specific organ or as a novel therapeutic agent. This review explores recent advances in green synthesized nanomaterials and their potential use against leukemia, especially focusing on silver (Ag) and gold (Au) nanostructures. In detail, we have reviewed various eco-friendly methods of bio-synthesized NPs, their analytical properties, and toxicity effects against leukemic models. This overview confirms the satisfactory potency of biogenic NPs toward leukemic cells and desirable safety profiles against human native cells, which opens a promising door toward commercializing these types of nontherapeutic agents if challenges involve clinical validations, reproducibility, and scalability could be resolved.
format Online
Article
Text
id pubmed-9171450
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-91714502022-06-08 Antineoplastic activity of biogenic silver and gold nanoparticles to combat leukemia: Beginning a new era in cancer theragnostic Mostafavi, Ebrahim Zarepour, Atefeh Barabadi, Hamed Zarrabi, Ali Truong, Linh B. Medina-Cruz, David Biotechnol Rep (Amst) Review Article The American Cancer Society estimated around 61,090 new cases of leukemia were diagnosed, and around 23,660 people died from this disease in the United States alone in 2021. Due to its burden on society, there is an unmet need to explore innovative approaches to overcome leukemia. Among different strategies that have been explored, nanotechnology appears to be a promising and effective approach for therapeutics. Specifically, biogenic silver and gold nanoparticles (NPs) have attracted significant attention for their antineoplastic activity toward leukemia cancer cells due to their unique physicochemical properties. Indeed, these nanostructures have emerged as useful approaches in anti-leukemic applications, either as carriers to enhance drug bioavailability and its targeted delivery to a specific organ or as a novel therapeutic agent. This review explores recent advances in green synthesized nanomaterials and their potential use against leukemia, especially focusing on silver (Ag) and gold (Au) nanostructures. In detail, we have reviewed various eco-friendly methods of bio-synthesized NPs, their analytical properties, and toxicity effects against leukemic models. This overview confirms the satisfactory potency of biogenic NPs toward leukemic cells and desirable safety profiles against human native cells, which opens a promising door toward commercializing these types of nontherapeutic agents if challenges involve clinical validations, reproducibility, and scalability could be resolved. Elsevier 2022-02-26 /pmc/articles/PMC9171450/ /pubmed/35686001 http://dx.doi.org/10.1016/j.btre.2022.e00714 Text en © 2022 The Author(s). Published by Elsevier B.V. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review Article
Mostafavi, Ebrahim
Zarepour, Atefeh
Barabadi, Hamed
Zarrabi, Ali
Truong, Linh B.
Medina-Cruz, David
Antineoplastic activity of biogenic silver and gold nanoparticles to combat leukemia: Beginning a new era in cancer theragnostic
title Antineoplastic activity of biogenic silver and gold nanoparticles to combat leukemia: Beginning a new era in cancer theragnostic
title_full Antineoplastic activity of biogenic silver and gold nanoparticles to combat leukemia: Beginning a new era in cancer theragnostic
title_fullStr Antineoplastic activity of biogenic silver and gold nanoparticles to combat leukemia: Beginning a new era in cancer theragnostic
title_full_unstemmed Antineoplastic activity of biogenic silver and gold nanoparticles to combat leukemia: Beginning a new era in cancer theragnostic
title_short Antineoplastic activity of biogenic silver and gold nanoparticles to combat leukemia: Beginning a new era in cancer theragnostic
title_sort antineoplastic activity of biogenic silver and gold nanoparticles to combat leukemia: beginning a new era in cancer theragnostic
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171450/
https://www.ncbi.nlm.nih.gov/pubmed/35686001
http://dx.doi.org/10.1016/j.btre.2022.e00714
work_keys_str_mv AT mostafaviebrahim antineoplasticactivityofbiogenicsilverandgoldnanoparticlestocombatleukemiabeginninganeweraincancertheragnostic
AT zarepouratefeh antineoplasticactivityofbiogenicsilverandgoldnanoparticlestocombatleukemiabeginninganeweraincancertheragnostic
AT barabadihamed antineoplasticactivityofbiogenicsilverandgoldnanoparticlestocombatleukemiabeginninganeweraincancertheragnostic
AT zarrabiali antineoplasticactivityofbiogenicsilverandgoldnanoparticlestocombatleukemiabeginninganeweraincancertheragnostic
AT truonglinhb antineoplasticactivityofbiogenicsilverandgoldnanoparticlestocombatleukemiabeginninganeweraincancertheragnostic
AT medinacruzdavid antineoplasticactivityofbiogenicsilverandgoldnanoparticlestocombatleukemiabeginninganeweraincancertheragnostic